Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
According to StreetInsider.com, the following companies may benefit from protection, therapy and/or vaccination against swine flu. Most of these are highly speculative so trade at your own risk.
Alpha Pro Tech (APT) - protects people with disposable protective apparel such as masks.
Generex Biotechnology (GNBT) - developing drug delivery systems.
Hemispherx BioPharma (HEB) - engaged in [...]
CombiMatrix (CBMX) is an ETF Innovators Emerging Diagnostics Index component and spin-off company from Acacia Research (ACTG) which has operated independently since August 2007 as a developer of DNA MicroArrays for lab-based personalized medicine applications to improve treatment outcomes, which are exempt from the more time-consuming and costly route of FDA approval as in vitro diagnostic products. The tests are also affordable, with a target price of $250-$300 on average. Today, CBMX announ (...)[More...]
With the surprise announcement last week by Geron (GERN) that the FDA would allow human clinical trials for embryonic stem cells, all companies in the underlying ETF Innovators Index to track the space are screaming higher again today – led by the company with the biggest gains over the past year, StemCells (STEM). Below are three additional areas and associated companies for investors to consider in the search of the next hot spots in the healthcare sector, including a focus on small/mid-cap companies which have the added potential to be acquired as part of renewed M&A in the sector this year. Molecular Diagnostics EXACT Sciences (EXAS) has rejected the hostile $1.50 all-stock offer from[More...]
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies[More...]
The accompanying table (click to enlarge) includes statistics for all 40 companies included in the ETF Innovators Emerging Diagnostics Index of stocks with market caps of less than $150M and an average market value of $50M. The index has lost nearly 54% of its value in the past year, compared to declines of about 40% each for the S&P 500 SPDR ETF (SPY) + iShares Russell Micro-Cap ETF (IWC), 29% for the Healthcare Sector SPDR (XLV), and 15% for the SPDR S&P Biotech ETF (XBI).<br[More...]
All News |
Breaking News |
Featured Stories